睿知中国疾病研究地图
候选清单0

南宁广西医科大学

广西医科大学附属肿瘤医院

Guangxi Medical University Cancer Hospital

在本站收录的 53 种疾病中,这家医院列在其中 9 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

广西医科大学附属肿瘤医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma48 篇牵头论文牵头 2 项开放试验
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma149 篇牵头论文牵头 2 项开放试验
  4. 胃癌Stomach cancer12 篇牵头论文
  5. 骨肉瘤Osteosarcoma4 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
  7. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  8. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
  9. 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、神经母细胞瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 48 篇,占 2.0%。

牵头论文
48
2021–2025 年
牵头试验
4
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
9
由其他机构牵头
每年牵头的论文数
2021: 8820212022: 121220222023: 9920232024: 8820242025: 11112025

南宁有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
    分期
    未注明
    开始
    2022-07
    登记号
    NCT05707819

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学附属肿瘤医院南宁

  2. 正在招募
    Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2020-06
    登记号
    NCT04376866

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:广西医科大学附属肿瘤医院南宁

  3. 正在招募
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
    分期
    III期
    开始
    2026-04
    登记号
    NCT07235319

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 4 家列出的医院为研究中心南宁、广州、杭州、福州、长沙

  4. 正在招募
    Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2026-07
    登记号
    NCT07528183

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 3 家列出的医院为研究中心南宁、广州、武汉、福州

  5. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  6. 正在招募
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    分期
    II期
    开始
    2025-04
    登记号
    NCT06839066

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心东莞、中山、南宁、广州、成都、杭州、武汉、深圳、福州、赣州、长沙

  7. 正在招募
    A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
    分期
    I/II期
    开始
    2025-11
    登记号
    NCT07258979

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、东莞、南宁、南昌、厦门、广州、成都、昆明、杭州、桂林、江门、海口、福州、重庆、长沙、韶关

  8. 正在招募
    喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    分期
    III期
    开始
    2025-12
    登记号
    NCT07311772

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  9. 正在招募
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    分期
    III期
    开始
    2025-11
    登记号
    NCT07328854

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心中山、南宁、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

  10. 正在招募
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    分期
    III期
    开始
    2024-03
    登记号
    NCT06239727

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 21 家列出的医院为研究中心东莞、佛山、南京、南宁、南昌、厦门、天津、广州、成都、杭州、武汉、汕头、海口、湛江、福州、西安、贵阳、重庆、长沙

  11. 正在招募
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    分期
    II期
    开始
    2024-06
    登记号
    NCT06455410

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学孙逸仙纪念医院;另有 7 家列出的医院为研究中心佛山、南宁、广州、柳州、汕头、深圳

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题影像与人工智能诱导/同步化疗放疗技术
论文中的科室放疗科影像/核医学科肿瘤内科耳鼻喉/头颈外科
牵头的论文48
  1. Development and Validation of a Nomogram Based on the Different Grades of Cervical Lymph Node Necrosis to Predict Overall Survival in Patients with Lymph Node-Positive Locally Advanced Nasopharyngeal Carcinoma.2025Academic radiology
  2. Early circulating EBV-DNA clearance predicts enhanced short-term treatment response and survival benefit in locally advanced nasopharyngeal carcinoma.2025BMC cancer免费全文
  3. Integrated machine learning and single-cell analysis identify chromatin-remodeling gene signature for diagnosis and prognosis in nasopharyngeal carcinoma.2025Clinical and experimental medicine免费全文
  4. Genetic algorithm-optimized neural network outperforms TNM staging in predicting rapidly progressive nasopharyngeal carcinoma: Reassessing adjuvant chemotherapy benefit via propensity score matching.2025European journal of cancer (Oxford, England : 1990)
  5. An interpretable machine learning model assists in predicting induction chemotherapy response and survival for locoregionally advanced nasopharyngeal carcinoma using MRI: a multicenter study.2025European radiology
  6. Machine learning-derived prognostic signature for progression-free survival in non-metastatic nasopharyngeal carcinoma.2025Head & neck
  7. Efficacy and safety of Anlotinib in combination with gemcitabine and cisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A single-arm clinical trial.2025International journal of cancer
  8. Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.2025Oral oncology
  9. Prognostic nomogram for synchronous metastatic nasopharyngeal carcinoma: a retrospective multicentre study.2025Radiation oncology (London, England)免费全文
  10. Four-dimensional trapped ion mobility spectrometry proteomics reveals circulating extracellular vesicles encapsulated drivers of nasopharyngeal carcinoma distant dissemination.2025Talanta
  11. Risk factors and clinical prediction model for vertebral artery stenosis following radiotherapy for nasopharyngeal carcinoma.2025The Journal of international medical research免费全文
  12. Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma.2024BMC cancer免费全文
  13. Nasopharyngeal cancer risk assessment by country or region worldwide from 1990 to 2019.2024BMC public health免费全文
  14. Deep learning model using planar whole-body bone scintigraphy for diagnosis of skull base invasion in patients with nasopharyngeal carcinoma.2024Journal of cancer research and clinical oncology免费全文
  15. Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.2024Oral oncology
  16. A nomogram based on circulating CD8+ T cell and platelet-to-lymphocyte ratio to predict overall survival of patients with locally advanced nasopharyngeal carcinoma.2024Radiation oncology (London, England)免费全文
  17. Efficacy of metastatic lesion radiotherapy in patients with metastatic nasopharyngeal carcinoma: A multicenter retrospective study.2024Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  18. Serum ferritin predicted prognosis in patients with nasopharyngeal carcinoma.2024Scientific reports免费全文
  19. Short-term OS as a surrogate endpoint for 5-year OS in nasopharyngeal carcinoma in non-endemic area.2024World journal of surgical oncology免费全文
  20. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis.2023Cancer biology & therapy免费全文
  21. Regional lymph node density-based nomogram predicts prognosis in nasopharyngeal carcinoma patients without distant metastases.2023Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  22. Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response.2023Cancer medicine免费全文
  23. STIM1-regulated exosomal EBV-LMP1 empowers endothelial cells with an aggressive phenotype by activating the Akt/ERK pathway in nasopharyngeal carcinoma.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  24. Long-term outcomes of chemoradiotherapy versus radiotherapy alone in patients with intermediate-risk nasopharyngeal carcinoma: a population-based analysis.2023European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  25. A dynamic nomogram combining tumor stage and magnetic resonance imaging features to predict the response to induction chemotherapy in locally advanced nasopharyngeal carcinoma.2023European radiology
  26. The miRNA-185-5p/STIM1 Axis Regulates the Invasiveness of Nasopharyngeal Carcinoma Cell Lines by Modulating EGFR Activation-Stimulated Switch from E- to N-Cadherin.2023Molecules (Basel, Switzerland)免费全文
  27. Efficacy of induction chemotherapy in lymph node-positive stage III nasopharyngeal carcinoma and identification of beneficiaries based on clinical features: A propensity score matching analysis.2023Oral oncology
  28. Research trends of radiation induced temporal lobe injury in patients with nasopharyngeal carcinoma from 2000 to 2022: a bibliometric analysis.2023Radiation oncology (London, England)免费全文
  29. Sleep, depression, and anxiety in family caregivers of nasopharyngeal carcinoma patients before therapy.2022Acta psychologica
  30. MRI-based random survival Forest model improves prediction of progression-free survival to induction chemotherapy plus concurrent Chemoradiotherapy in Locoregionally Advanced nasopharyngeal carcinoma.2022BMC cancer免费全文
  31. Efficiency of high cumulative cisplatin dose in high- and low-risk patients with locoregionally advanced nasopharyngeal carcinoma.2022Cancer medicine免费全文
  32. A spectral CT-based nomogram for predicting the response to induction chemotherapy in nasopharyngeal carcinoma.2022Clinical radiology
  33. Nasopharyngeal Carcinoma Progression: Accumulating Genomic Instability and Persistent Epstein-Barr Virus Infection.2022Current oncology (Toronto, Ont.)免费全文
  34. A nomogram to predict survival and guide individualized induction chemotherapy in T3-4N1M0 nasopharyngeal carcinoma.2022Current problems in cancer
  35. Downregulation of annexin A3 promotes ionizing radiation-induced EGFR activation and nuclear translocation and confers radioresistance in nasopharyngeal carcinoma.2022Experimental cell research
  36. Development and validation of prognostic nomograms in patients with ascending type of nasopharyngeal carcinoma: Retrospective study based on SEER database.2022Head & neck
  37. Prognostic significance of wait time for radical radiotherapy in locoregionally advanced nasopharyngeal carcinoma.2022Head & neck
  38. A nomogram based on tumor response to induction chemotherapy may predict survival in locoregionally advanced nasopharyngeal carcinoma.2022Head & neck
  39. MRI-Based Back Propagation Neural Network Model as a Powerful Tool for Predicting the Response to Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.2022Journal of magnetic resonance imaging : JMRI
  40. Survival among subgroups of patients with stage II nasopharyngeal carcinoma.2022Scientific reports免费全文
  41. Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study.2021Clinical nutrition (Edinburgh, Scotland)
  42. Effect of chemotherapy on survival in patients with stage T3-4N0M0 nasopharyngeal carcinoma.2021Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
  43. PADI4, negatively regulated by miR-335-5p, participates in regulating the proliferation, migration, invasion and radiosensitivity of nasopharyngeal carcinoma cells.2021Journal of biological regulators and homeostatic agents
  44. Polyethylene glycol-coated ultrasmall superparamagnetic iron oxide nanoparticles-coupled sialyl Lewis X nanotheranostic platform for nasopharyngeal carcinoma imaging and photothermal therapy.2021Journal of nanobiotechnology免费全文
  45. CD166 promotes cancer stem cell-like phenotype via the EGFR/ERK1/2 pathway in the nasopharyngeal carcinoma cell line CNE-2R.2021Life sciences
  46. Maximal lymph nodal diameter on N stage of nasopharyngeal carcinoma.2021Medicine免费全文
  47. Retropharyngeal lymph node metastasis on N stage of nasopharyngeal carcinoma.2021PloS one免费全文
  48. Validation of Stage N3 of the Eighth Edition AJCC Staging System for Nasopharyngeal Carcinoma.2021The Laryngoscope
中文论文(未计入)1
  1. [Progress of scRNA-seq technology in nasopharyngeal carcinoma research].2025Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
  1. Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma正在招募NCT05707819牵头方2022-07 启动
  2. Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma正在招募NCT04376866牵头方III期2020-06 启动
  3. Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial状态不明NCT04992988牵头方II期2020-06 启动
  4. The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma状态不明NCT02116231牵头方II期2014-04 启动
  5. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma正在招募NCT07528183研究中心II期2026-07 启动
  6. PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC正在招募NCT07235319研究中心III期2026-04 启动
  7. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid正在招募NCT07311772研究中心III期2025-12 启动
  8. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  9. A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.正在招募NCT07258979研究中心I/II期2025-11 启动
  10. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma正在招募NCT07328854研究中心III期2025-11 启动
  11. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy正在招募NCT06839066研究中心II期2025-04 启动
  12. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response正在招募NCT06239727研究中心III期2024-03 启动
  13. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma正在招募NCT06455410研究中心II期2024-06 启动
  14. Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma进行中,不再招募NCT06712888研究中心III期2025-02 启动
  15. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT05126719研究中心II期2023-04 启动
  16. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)进行中,不再招募NCT05587374研究中心III期2023-08 启动
  17. TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma已完成NCT05563480研究中心II期2022-10 启动
  18. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma进行中,不再招募NCT04907370研究中心III期2021-08 启动
  19. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma进行中,不再招募NCT04974398研究中心III期2021-08 启动
  20. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)已完成NCT03924986研究中心III期2019-03 启动
  21. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma状态不明NCT03427827研究中心III期2018-07 启动
  22. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma状态不明NCT03700476研究中心III期2018-12 启动
  23. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma状态不明NCT02633176研究中心III期2015-01 启动
  24. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT02944708研究中心III期2015-10 启动
  25. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)32
  1. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Research会议摘要
  2. An Integrated Analysis of RNA Sequencing and Molecular Docking Reveal EIF2AK2, IFIT1, and STAT1 as Key Targets of EGCG in Nasopharyngeal Carcinoma2025Research Square预印本
  3. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncology论文
  4. Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.2025Journal of Clinical Oncology会议摘要
  5. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncology会议摘要
  6. Multi-Omics Mendelian Randomization Integrating GWAS, eQTL, RNA-seq and Cell Line Experiment Reveal GLIPR1 and ARHGAP11A as Potential Targets of EGCG for Nasopharyngeal Carcinoma2025Research Square预印本
  7. Optimization of the 9th Ajcc/Uicc Tnm Staging System for Nasopharyngeal Carcinoma Based on Age and Pretreatment Ebv DNA: Exploring Prognostic Stratification and Individualized Treatment Strategies for Stage Ii-Iii Patients2025SSRN Electronic Journal预印本
  8. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncology论文
  9. Semen podocarpi extract enhances radiosensitivity in nasopharyngeal carcinoma cells via Raf/MEK/ERK signaling pathway2025Asian Pacific Journal of Tropical Biomedicine论文
  10. Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car2025Journal of Clinical Oncology会议摘要
  11. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncology会议摘要
  12. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncology会议摘要
  13. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncology会议摘要
  14. Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.2024Journal of Clinical Oncology会议摘要
  15. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncology会议摘要
  16. Prognostic Analysis of Nonmetastatic Nasopharyngeal Carcinoma in Older Patients Undergoing Intensity‐Modulated Radiotherapy2024International Journal of Clinical Practice论文
  17. Safety and efficacy of iparomlimab and tuvonralimab in combination with gemcitabine and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 trial (DUBHE-N-2024Journal of Clinical Oncology会议摘要
  18. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncology论文
  19. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncology会议摘要
  20. A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).2022Journal of Clinical Oncology会议摘要
  21. Analysis of hnRNP K Expression and Relevance for Clinical Outcomes in Hepatocellular carcinoma2022Research Square预印本
  22. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  23. Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.2022Journal of Clinical Oncology会议摘要
  24. Upregulation of ITGAV and the underlying mechanisms in nasopharyngeal carcinoma2022Electronic Journal of Biotechnology论文
  25. ZBTB7A governs 2-DG-inhibited glycolysis by regulating GLUT1 in nasopharyngeal carcinoma2022Biocell论文
  26. 436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy2021Journal for ImmunoTherapy of Cancer会议摘要
  27. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文
  28. A Nomogram to Predict Survival and Determine Necessity of Induction Chemotherapy for Patients With Stage T3-4N1 Nasopharyngeal Carcinoma2021Research Square预印本
  29. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.2021Journal of Clinical Oncology会议摘要
  30. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要
  31. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncology会议摘要
  32. Potential Role of The Upregulation of The Zinc Finger Protein of The Cerebellum 2 In Nasopharyngeal Carcinoma2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 3320242025: 002025

南宁有 4 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    分期
    II期
    开始
    2026-08
    登记号
    NCT07700667

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心南京、南宁、南昌、哈尔滨、天津、太原、成都、昆明、汕头、沈阳、洛阳、石家庄、福州、西安、郑州、长春

  2. 正在招募
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    分期
    III期
    开始
    2025-03
    登记号
    NCT06644781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 28 家列出的医院为研究中心临沂、北京、南宁、厦门、合肥、哈尔滨、天津、安阳、成都、扬州、新乡、杭州、武汉、汕头、沈阳、洛阳、济南、济宁、福州、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题放疗新辅助与综合治疗手术
论文中的科室放疗科
牵头的论文3
  1. The predictors of lymphopenia and its effects on survival in locally advanced esophageal squamous cell carcinoma.2024Cancer biology & therapy免费全文
  2. Adjuvant treatment patterns for pT3N0M0 esophageal cancer undergoing surgery.2024Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  3. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.2024Frontiers in immunology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
  1. SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma正在招募NCT07700667研究中心II期2026-08 启动
  2. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)正在招募NCT06644781研究中心III期2025-03 启动
  3. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  4. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  5. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  6. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  7. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
PubMed 以外找到的论文(未计入)5
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. Research on the Expression and Mechanism of LRRC8D in Esophageal Squamous Cell Carcinoma2025Research Square预印本
  3. O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncology论文
  4. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  5. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncology论文

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 149 篇,占 1.0%。

牵头论文
149
2021–2025 年
牵头试验
10
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 222220212022: 292920222023: 313120232024: 323220242025: 32322025

南宁有 5 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adjuvant TACE in HCC With High-risk Recurrence Factors
    分期
    III期
    开始
    2026-02
    登记号
    NCT07417397

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:广西医科大学附属肿瘤医院南宁

  2. 正在招募
    Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
    分期
    II/III期
    开始
    2021-06
    登记号
    NCT05062837

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:广西医科大学附属肿瘤医院南宁

  3. 正在招募
    A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
    分期
    I/II期
    开始
    2026-05
    登记号
    NCT07547553

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、沈阳、福州、蚌埠、长春

  4. 正在招募
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    分期
    I期
    开始
    2025-11
    登记号
    NCT07176650

    年龄 18 岁 至 65 岁(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、天津、广州、成都、杭州、武汉、沈阳、海口、石家庄、福州、蚌埠、西安、郑州、长春

  5. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  6. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、福州、重庆、长沙

  7. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后手术与肝移植影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科病理/检验科肿瘤内科放疗科
牵头的论文149
  1. Machine learning models for predicting microvascular invasion in hepatocellular carcinoma with three-dimensional whole-lesion 18F-FDG PET radiomics.2026Hellenic journal of nuclear medicine
  2. Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy.2026Hepatology (Baltimore, Md.)
  3. Genome-wide association study of HBV-related hepatocellular carcinoma identifies a functional variant at the FAM114A1 locus.2026Journal of genetics and genomics = Yi chuan xue bao
  4. Bimetallic Ca/Zn Nanoagonist Remould the Immunosuppressive Hepatocellular Carcinoma Microenvironment Following Incomplete Microwave Ablation via Pyroptosis and the STING Signaling Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  5. Immune infiltration landscape and potential drug-targeted implications for hepatocellular carcinoma with 'progression/hyper-progression' recurrence.2025Annals of medicine免费全文
  6. Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.2025BMC cancer免费全文
  7. Platelet-albumin-bilirubin versus albumin-bilirubin as a predictor of long-term survival for hepatitis B-Induced hepatocellular carcinoma after hepatic resection.2025BMC cancer免费全文
  8. C-reactive protein to albumin ratio combined with the Systemic Inflammatory Response Index predicts the prognosis of patients undergoing radical hepatectomy.2025BMC cancer免费全文
  9. Multi-omics integration analysis of the amino-acid metabolism-related genes identifies putatively causal variants of ACCS associated with hepatitis B virus-related hepatocellular carcinoma survival.2025BMC cancer免费全文
  10. CK19 protein expression: the best cutoff value on the prognosis and the prognosis model of hepatocellular carcinoma.2025BMC cancer免费全文
  11. Tumor vascular occlusion by calcium-based thermosensitizer provokes continuous cavitation effect and thermal energy transition efficiency of radiofrequency ablation therapy.2025Biomaterials
  12. Comprehensive strategies for management of postoperative hyper-progression recurrence (HPR) of hepatocellular carcinoma: a 12-year large sample multi-center study.2025Cancer biology & medicine免费全文
  13. HBX Multi-Mutations Combined With Traditional Screening Indicators to Establish a Nomogram Contributes to Precisely Stratify the High-Risk Population of Hepatocellular Carcinoma.2025Cancer medicine免费全文
  14. CTSE inhibits anti-tumor T cell response by promoting des-γ-carboxy prothrombin releasing in hepatocellular carcinoma.2025Cell death & disease免费全文
  15. lncSNHG16 promotes hepatocellular carcinoma development by inhibiting autophagy.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  16. Novel genetic variants in the NLRP3 inflammasome-related PANX1 and APP genes predict survival of patients with hepatitis B virus-related hepatocellular carcinoma.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico免费全文
  17. Prognostic nomogram for hepatocellular carcinoma with major vascular invasion: a population-based study from the SEER database and a Chinese cohort.2025European journal of medical research免费全文
  18. Up-regulated ITGB4 promotes hepatocellular carcinoma metastasis by activating hypoxia-mediated glycolysis and cancer-associated fibroblasts.2025European journal of pharmacology
  19. Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoin2025Frontiers in cellular and infection microbiology免费全文
  20. Development of a machine learning model to predict overall survival for large hepatocellular carcinoma at BCLC stage A or B after curative hepatectomy.2025Frontiers in immunology免费全文
  21. Predicting recurrence and recurrence-free survival in initially unresectable hepatocellular carcinoma: a novel nomogram for patients undergoing conversion hepatectomy with lenvatinib, PD-1 inhibitor, and interventional therapy.2025Frontiers in immunology免费全文
  22. The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.2025Frontiers in immunology免费全文
  23. Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis.2025Frontiers in immunology免费全文
  24. Clonorchis sinensis-infected hepatocellular carcinoma exhibits distinct tumor microenvironment and molecular features.2025Frontiers in immunology免费全文
  25. Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit i2025Hepatology (Baltimore, Md.)
  26. MSNs-loaded HMME and Erastin-mediated ferroptosis combined with sonodynamic therapy for HCC treatment.2025Journal of cancer research and therapeutics
  27. Disruption of mitochondrial homeostasis by bimetallic ca/cu nanocomposites against hepatocellular carcinoma.2025Journal of controlled release : official journal of the Controlled Release Society
  28. Prognostic analysis and limited efficacy of adjuvant TACE in hepatocellular carcinoma following hepatectomy: a propensity score-matched study.2025Langenbeck's archives of surgery免费全文
  29. Impact of Clonorchis sinensis infection on long-term survival after curative resection for hepatocellular carcinoma: A multicenter cohort study.2025PLoS neglected tropical diseases免费全文
  30. Multi-omics analysis of lactate metabolism gene regulation in Clonorchis sinensis-associated hepatocellular carcinoma.2025Parasites & vectors免费全文
  31. Clonorchis sinensis infection remodels chromatin accessibility in hepatocellular carcinoma.2025Parasites & vectors免费全文
  32. The microRNA landscape and regulatory network in Clonorchis sinensis-infected hepatocellular carcinoma: implications for tumor progression.2025Parasites & vectors免费全文
  33. Lysyl oxidase as a potential biomarker of lung recurrence after hepatectomy in hepatocellular carcinoma.2025Scientific reports免费全文
  34. Sleep quality trajectories and their relationship with quality of life in patients with hepatocellular carcinoma: a prospective cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  35. Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.2025World journal of surgical oncology免费全文
  36. Silencing of KIF2C enhances the sensitivity of hepatocellular carcinoma cells to cisplatin through regulating the PI3K/AKT/MAPK signaling pathway.2024Anti-cancer drugs
  37. Genetic variants in m5C modification genes are associated with survival of patients with HBV-related hepatocellular carcinoma.2024Archives of toxicology
  38. Prognostic value of aspartate aminotransferase/alanine aminotransferase ratio in hepatocellular carcinoma after hepatectomy.2024BJS open免费全文
  39. Prognostic importance of the Scottish inflammatory prognostic score in patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study.2024BMC cancer免费全文
  40. Associations between modifiable risk factors and hepatocellular carcinoma: a trans-ancestry Mendelian randomization study.2024BMC cancer免费全文
  41. A novel surgical scheme for hepatectomy in hepatocellular carcinoma patients with clinically significant portal hypertension.2024BMC cancer免费全文
  42. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.2024BMC cancer免费全文
  43. Nomogram for Predicting Postoperative Pulmonary Metastasis in Hepatocellular Carcinoma Based on Inflammatory Markers.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  44. Potentially functional genetic variants in ferroptosis-related CREB3 and GALNT14 genes predict survival of hepatitis B virus-related hepatocellular carcinoma.2024Cancer medicine免费全文
  45. Association between novel genetic variants of Notch signaling pathway genes and survival of hepatitis B virus-related hepatocellular carcinoma.2024Cancer medicine免费全文
  46. Functional genetic variants of the disulfidptosis-related INF2 gene predict survival of hepatitis B virus-related hepatocellular carcinoma.2024Carcinogenesis
  47. Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  48. Comprehensive analysis of the role of Netrin G1 (NTNG1) in hepatocellular carcinoma cells.2024European journal of pharmacology
  49. Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance.2024Frontiers in immunology免费全文
  50. Dynamics trajectory of patient-reported quality of life and its associated risk factors among hepatocellular carcinoma patients receiving immune checkpoint inhibitors: a prospective cohort study.2024Frontiers in immunology免费全文
  51. Developing an advanced diagnostic model for hepatocellular carcinoma through multi-omics integration leveraging diverse cell-death patterns.2024Frontiers in immunology免费全文
  52. Integrating single-cell and bulk RNA sequencing reveals CK19 + cancer stem cells and their specific SPP1 + tumor-associated macrophage niche in HBV-related hepatocellular carcinoma.2024Hepatology international
  53. Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation.2024International journal of nanomedicine免费全文
  54. Development and validation of a nomogram for radiation-induced hepatic toxicity after intensity modulated radiotherapy for hepatocellular carcinoma: a retrospective study.2024Japanese journal of clinical oncology免费全文
  55. Genetic variants of m6A modification genes are associated with survival of HBV-related hepatocellular carcinoma.2024Journal of cellular and molecular medicine免费全文
  56. Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study.2024Langenbeck's archives of surgeryRCT
  57. Two case reports of breast cancer combined with synchronous primary intrahepatic cholangiocarcinoma/mixed liver cancer.2024Medicine免费全文
  58. Prevalence of Malnutrition in Patients with Hepatocellular Carcinoma: A Comparative Study of GLIM Criteria, NRS2002, and PG-SGA, and Identification of Independent Risk Factors.2024Nutrition and cancer
  59. Involvement of lncRNAs in the regulation of aerobic glycolysis in hepatocellular carcinoma: Main functions, regulatory mechanisms and potential therapeutic implications (Review).2024Oncology reports免费全文
  60. Clonorchis sinensis infection contributes to hepatocellular carcinoma progression via enhancing angiogenesis.2024PLoS neglected tropical diseases免费全文
  61. Clonorchis sinensis on the prognosis of patients with spontaneous rupture of Hepatocellular Carcinoma: An inverse probability of treatment weighting analysis.2024PLoS neglected tropical diseases免费全文
  62. Clonorchis sinensis infection amplifies hepatocellular carcinoma stemness, predicting unfavorable prognosis.2024PLoS neglected tropical diseases免费全文
  63. Associations of tumor-related psychiatric symptoms and healthy behaviors with dynamic quality of life after hepatocellular carcinoma hepatectomy.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer免费全文
  64. Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial.2024Trials免费全文
  65. The dynamic variation position and predominant quasispecies of hepatitis B virus: Novel predictors of early hepatocarcinoma.2024Virus research免费全文
  66. Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era.2024World journal of gastroenterology免费全文
  67. Risk factors and nomogram predictive models for postsurgical progression/hyperprogression recurrence in hepatocellular carcinoma with macroscopic vascular invasion.2024World journal of surgical oncology免费全文
  68. A Reliable and Repeatable Model for Predicting Microvascular Invasion in Patients With Hepatocellular Carcinoma.2023Academic radiology
  69. Serum immune biomarker levels combined with hepatitis B virus infection status predict early recurrence of early-stage hepatocellular carcinoma with microvascular invasion after liver resection.2023Acta chirurgica Belgica
  70. Letter: Entecavir versus tenofovir on serum lipoprotein levels of hepatitis B virus-related hepatocellular carcinoma after curative hepatectomy.2023Alimentary pharmacology & therapeutics
  71. Letter: repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma in ideal candidates.2023Alimentary pharmacology & therapeutics
  72. Specific gut microbiome signature predicts hepatitis B virus-related hepatocellular carcinoma patients with microvascular invasion.2023Annals of medicine免费全文
  73. Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization.2023Annals of medicine免费全文
  74. Genetic variants of SOS2, MAP2K1 and RASGRF2 in the RAS pathway genes predict survival of HBV-related hepatocellular carcinoma patients.2023Archives of toxicology
  75. Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses.2023Asia-Pacific journal of clinical oncology
  76. Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis.2023BJS open免费全文
  77. Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy.2023BMC cancer免费全文
  78. The association of serum IL-33/ST2 expression with hepatocellular carcinoma.2023BMC cancer免费全文
  79. Mesenchymal circulating tumor cells and Ki67: their mutual correlation and prognostic implications in hepatocellular carcinoma.2023BMC cancer免费全文
  80. Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol.2023BMJ open免费全文
  81. Nomograms for postsurgical extrahepatic recurrence prediction of hepatocellular carcinoma based on presurgical circulating tumor cell status and clinicopathological factors.2023Cancer medicineRCT免费全文
  82. Association between telomere length and hepatocellular carcinoma risk: A Mendelian randomization study.2023Cancer medicine免费全文
  83. miR-17-5p slows progression of hepatocellular carcinoma by downregulating TGFβR2.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  84. Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions - A Systematic Review and Network Meta-analysis.2023Clinical oncology (Royal College of Radiologists (Great Britain))
  85. Down-regulation of ALDOB during metabolic reprogramming mediates malignant behavior in hepatocellular carcinoma and insensitivity to postoperative adjuvant transarterial chemoembolization.2023Clinical science (London, England : 1979)
  86. Novel Long Noncoding RNAs, LINC01093 and MYLK-AS1, Serve as Potential Diagnostic and Prognostic Biomarkers or Hepatocellular Carcinoma.2023DNA and cell biology
  87. Is hepatectomy feasible for hepatocellular carcinoma patients with clinically significant portal hypertension and beyond the Milan criteria?2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  88. Comparison of survival rates as predicted by total tumor volume or tumor burden score in patients with hepatocellular carcinoma concurrent with fatty liver disease and hepatitis B virus.2023Expert review of gastroenterology & hepatology
  89. A functional variant in the RAD51 3' UTR is associated with survival of hepatocellular carcinoma patients.2023Gene
  90. A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma.2023International journal of molecular sciences免费全文
  91. The Novel-Natural-Killer-Cell-Related Gene Signature Predicts the Prognosis and Immune Status of Patients with Hepatocellular Carcinoma.2023International journal of molecular sciences免费全文
  92. Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study.2023Journal of gastroenterology
  93. Potentially functional genetic variants in RPS6KA4 and MAP2K5 in the MAPK signaling pathway predict HBV-related hepatocellular carcinoma survival.2023Molecular carcinogenesis
  94. Effects of Clonorchis sinensis combined with Hepatitis B virus infection on the prognosis of patients with Hepatocellular Carcinoma following Hepatectomy.2023PLoS neglected tropical diseases免费全文
  95. Radiotherapy plus anti-PD1 versus radiotherapy for hepatic toxicity in patients with hepatocellular carcinoma.2023Radiation oncology (London, England)免费全文
  96. Establishment and validation of a prognostic pomogram in unresectable hepatocellular carcinoma treated with intensity modulated radiotherapy: a real world study.2023Radiation oncology (London, England)免费全文
  97. Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child-Pugh grade B patients with locally advanced hepatocellular carcinoma.2023Radiation oncology (London, England)免费全文
  98. A three-gene signature reveals changes in the tumor immune microenvironment in the progression from NAFLD to HCC.2023Scientific reports免费全文
  99. Efficacy comparison of optimal treatments for hepatocellular carcinoma patients with portal vein tumor thrombus.2022Annals of hepatologyRCT
  100. Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis.2022BJS open免费全文
  101. Prognostic value of a nomogram based on peripheral blood immune parameters in unresectable hepatocellular carcinoma after intensity-modulated radiotherapy.2022BMC gastroenterologyRCT免费全文
  102. Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy.2022BMC gastroenterology免费全文
  103. Combination of Preoperative Circulating Tumor Cell Count and Neutrophil-Lymphocyte Ratio for Prognostic Prediction in Hepatocellular Carcinoma Patients after Curative Hepatectomy.2022BioMed research international免费全文
  104. Fatty acid binding protein 5 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by degradation of Krüppel-like factor 9 mediated by miR-889-5p via cAMP-response element binding protein.2022Cancer biology & therapy免费全文
  105. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.2022Cancer immunology, immunotherapy : CII免费全文
  106. The positive feedback loop of furin and TGFβ1 enhances the immune responses of Tregs to hepatocellular carcinoma cells and hepatitis B virus in vitro.2022Cell biology international
  107. Inflammation and Fibrosis in Patients with Non-Cirrhotic Hepatitis B Virus-Associated Hepatocellular Carcinoma: Impact on Prognosis after Hepatectomy and Mechanisms Involved.2022Current oncology (Toronto, Ont.)免费全文
  108. A functional liver imaging score for preoperative prediction of liver failure after hepatocellular carcinoma resection.2022European radiology
  109. CCNB1 promotes the development of hepatocellular carcinoma by mediating DNA replication in the cell cycle.2022Experimental biology and medicine (Maywood, N.J.)免费全文
  110. Second-line treatment options for hepatocellular carcinoma: current state and challenges for the future.2022Expert opinion on investigational drugs
  111. A novel risk score based on immune-related genes for hepatocellular carcinoma as a reliable prognostic biomarker and correlated with immune infiltration.2022Frontiers in immunology免费全文
  112. Influence of clear cell carcinoma on the post-hepatectomy prognosis of patients with hepatocellular carcinoma.2022Future oncology (London, England)
  113. A new biomarker to enhance the radiosensitivity of hepatocellular cancer: miRNAs.2022Future oncology (London, England)
  114. Developmental artificial neural network model to evaluate the preoperative safe limit of future liver remnant volume for HCC combined with clinically significant portal hypertension.2022Future oncology (London, England)
  115. Outcomes of postoperative adjuvant transarterial chemoembolization for hepatocellular carcinoma according to the Ki67 index.2022Future oncology (London, England)
  116. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial.2022Hepatology international免费全文
  117. Arecoline promotes proliferation and migration of human HepG2 cells through activation of the PI3K/AKT/mTOR pathway.2022Hereditas免费全文
  118. Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta-analysis.2022Journal of gastroenterology and hepatology
  119. Clinical implications and biological features of a novel postoperative recurrent HCC classification: A multi-centre study.2022Liver international : official journal of the International Association for the Study of the Liver
  120. Effect of Body Composition on Outcomes in Patients with Hepatocellular Carcinoma Undergoing Radiotherapy: A Retrospective Study.2022Nutrition and cancer
  121. Integrative Analysis Reveals the Potential Role and Prognostic Value of GOLM1 in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevity免费全文
  122. Clonorchis sinensis infection contributes to hepatocellular carcinoma progression in rat.2022Parasitology research
  123. Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation.2022Pathology oncology research : POR免费全文
  124. Holliday Cross-Recognition Protein HJURP: Association With the Tumor Microenvironment in Hepatocellular Carcinoma and With Patient Prognosis.2022Pathology oncology research : POR免费全文
  125. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.2022Radiation oncology (London, England)免费全文
  126. Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy.2022World journal of surgical oncology免费全文
  127. Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy.2022World journal of surgical oncology免费全文
  128. Morphine may act via DDX49 to inhibit hepatocellular carcinoma cell growth.2021Aging免费全文
  129. Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection.2021Alimentary pharmacology & therapeutics
  130. Response to Comment on "'Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma': A 'Minimally-invasive' Step Forward".2021Annals of surgery
  131. Development and Validation of a Nomogram to Preoperatively Estimate Post-hepatectomy Liver Dysfunction Risk and Long-term Survival in Patients With Hepatocellular Carcinoma.2021Annals of surgery
  132. lncRNA Expression-Based Risk Scoring System Can Predict Survival of Tumor-Positive Patients with Hepatocellular Carcinoma.2021Asian Pacific journal of cancer prevention : APJCP免费全文
  133. Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion.2021BMC cancer免费全文
  134. Safe standard remnant liver volume after hepatectomy in HCC patients in different stages of hepatic fibrosis.2021BMC surgery免费全文
  135. Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma.2021BioMed research international免费全文
  136. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients.2021Bioscience reports免费全文
  137. Combination of serum paraoxonase/arylesterase 1 and antithrombin-III is a promising non-invasion biomarker for discrimination of AFP-negative HCC versus liver cirrhosis patients.2021Clinics and research in hepatology and gastroenterology
  138. Preoperative MR imaging for predicting early recurrence of solitary hepatocellular carcinoma without microvascular invasion.2021European journal of radiology
  139. Preoperative normalized iodine concentration derived from spectral CT is correlated with early recurrence of hepatocellular carcinoma after curative resection.2021European radiology
  140. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.2021Frontiers in immunology免费全文
  141. Development and validation of prognostic nomograms in patients with hepatocellular carcinoma: a population-based study.2021Future oncology (London, England)
  142. Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.2021Hepatology international
  143. S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma.2021Hepatology international
  144. Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  145. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  146. Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma.2021Medicine免费全文
  147. C-terminal-truncated hepatitis B virus X protein promotes hepatocarcinogenesis by activating the MAPK pathway.2021Microbial pathogenesis
  148. Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study.2021Radiation oncology (London, England)免费全文
  149. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: retrospective multicentre study.2021The British journal of surgery
中文论文(未计入)2
  1. [CCDC97 influences the immune microenvironment and biological functions in HCC].2025Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. Advances in post-operative prognostic models for hepatocellular carcinoma.2023Journal of Zhejiang University. Science. B免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)24
  1. Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma状态不明NCT05131698牵头方早期I期2021-03 启动
  2. A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection状态不明NCT03914352牵头方不分期2019-04 启动
  3. Adjuvant TACE in HCC With High-risk Recurrence Factors正在招募NCT07417397牵头方(推断)III期2026-02 启动
  4. Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC正在招募NCT05062837牵头方(推断)II/III期2021-06 启动
  5. A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence已终止NCT06851104牵头方(推断)II期2025-02 启动
  6. HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC已完成NCT05532319牵头方(推断)II期2022-11 启动
  7. DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma状态不明NCT04229355牵头方(推断)III期2021-02 启动
  8. Association Between Autologous Transfusion and Recurrence-free Survival in Patients With HCC After Resection已完成NCT02654028牵头方(推断)不分期2019-01 启动
  9. Albumin for Hepatocellular Carcinoma状态不明NCT03974074牵头方(推断)III期2019-03 启动
  10. Celebrex and Metformin for Postoperative Hepatocellular Carcinoma状态不明NCT03184493牵头方(推断)III期2017-06 启动
  11. A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC正在招募NCT07547553研究中心I/II期2026-05 启动
  12. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  13. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma正在招募NCT07176650研究中心I期2025-11 启动
  14. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  15. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  16. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma进行中,不再招募NCT04712643研究中心III期2021-03 启动
  17. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev进行中,不再招募NCT04649489研究中心III期2021-04 启动
  18. A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation进行中,不再招募NCT04639180研究中心III期2021-04 启动
  19. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)已终止NCT04246177研究中心III期2020-05 启动
  20. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)进行中,不再招募NCT04344158研究中心III期2020-08 启动
  21. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma进行中,不再招募NCT04194775研究中心III期2019-12 启动
  22. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  23. Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry已完成NCT03233360研究中心2017-04 启动
  24. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects状态不明NCT03236636研究中心III期2017-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.1%。

牵头论文
12
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 3320222023: 0020232024: 3320242025: 112025

南宁有 2 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
    分期
    II/III期
    开始
    2026-03
    登记号
    NCT07221149

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、南宁、广州、福州

  2. 正在招募
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    分期
    I/II期
    开始
    2024-07
    登记号
    NCT06427941

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心南宁、南昌、合肥、哈尔滨、广州、徐州、成都、杭州、武汉、温州、石家庄、重庆、长沙

  3. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  4. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  5. 即将招募
    Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial
    分期
    不分期
    开始
    2026-10
    登记号
    NCT07561073

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心南宁

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像与人工智能腹膜转移与晚期化疗与综合治疗
论文中的科室消化/肝病科肿瘤内科肾内科
牵头的论文12
  1. Stacking classifiers based on integrated machine learning model: fusion of CT radiomics and clinical biomarkers to predict lymph node metastasis in locally advanced gastric cancer patients after neoadjuvant chemotherapy.2025BMC cancer免费全文
  2. Fruquintinib plus oxaliplatin combined with S-1 (SOX) as neoadjuvant therapy for locally advanced gastric cancer (GC) or gastro-oesophageal junction adenocarcinoma (GEJ): a multicentre, phase II, single-arm, open-label clinical trial (FRUTI2024BMJ open免费全文
  3. Regulation of the PD-1/PD-L1 Axis and NK Cell Dysfunction by Exosomal miR-552-5p in Gastric Cancer.2024Digestive diseases and sciences免费全文
  4. Random survival forest algorithm for risk stratification and survival prediction in gastric neuroendocrine neoplasms.2024Scientific reports免费全文
  5. LTBP2 Knockdown Promotes Ferroptosis in Gastric Cancer Cells through p62-Keap1-Nrf2 Pathway.2022BioMed research international免费全文
  6. Effect of Esophagus-Remnant Stomach Anterior Wall Anastomosis on Postoperative Reflux and Nutritional Status in Patients with Early- and Intermediate-Stage Proximal Gastric Cancer.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  7. Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients.2022Journal of surgical oncology
  8. Identified a disintegrin and metalloproteinase with thrombospondin motifs 6 serve as a novel gastric cancer prognostic biomarker by bioinformatics analysis.2021Bioscience reports免费全文
  9. Diagnostic and prognostic value of plasma heat shock protein 90alpha in gastric cancer.2021International immunopharmacology
  10. Percentage of Natural Killer (NK) Cells in Peripheral Blood Is Associated with Prognosis in Patients with Gastric Cancer: A Retrospective Study from a Single Center.2021Medical science monitor : international medical journal of experimental and clinical research免费全文
  11. Identification and verification of the molecular mechanisms and prognostic values of the cadherin gene family in gastric cancer.2021Scientific reports免费全文
  12. A Novel Nomogram for Individually Predicting of Vascular Invasion in Gastric Cancer.2021Technology in cancer research & treatment免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma状态不明NCT05122091牵头方(推断)II期2021-11 启动
  2. Stomach-Partitioning Versus Conventional Gastrojejunostomy for Malignant Gastric Outlet Obstruction: A Multicenter Randomized Controlled Trial即将招募NCT07561073研究中心不分期2026-10 启动
  3. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)正在招募NCT07221149研究中心II/III期2026-03 启动
  4. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors正在招募NCT06427941研究中心I/II期2024-07 启动
  5. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  6. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  7. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)进行中,不再招募NCT06356311研究中心III期2024-05 启动
  8. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  9. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  10. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  11. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 2220242025: 002025

南宁有 12 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室放疗科

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

南宁有 3 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    分期
    II/III期
    开始
    2026-05
    登记号
    NCT07379047

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、成都、昆明、杭州、武汉、济南、石家庄、福州、贵阳、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)正在招募NCT07379047研究中心II/III期2026-05 启动
  2. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

南宁有 3 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

南宁有 2 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
牵头的论文1
  1. To analyze the efficacy and safety of plasma exchange in the treatment of anti-NMDA receptor encephalitis.2026Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy

打开 PubMed 检索ClinicalTrials.gov

其他疾病

家族性腺瘤性息肉病

Familial adenomatous polyposis

2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

南宁有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

广西医科大学附属肿瘤医院

Guangxi Medical University Cancer Hospital

南宁

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Affiliated Tumor Hospital of Guangxi Medical University; Affiliated Cancer Hospital of Guangxi Medical University; Cancer Hospital of Guangxi Medical University; Affiliated Tumour Hospital of Guangxi Medical University; Guangxi Medical University Affiliated Tumor Hospital; Tumor Hospital of Guangxi Medical University; Guangxi Cancer Institute; Guangxi Cancer Molecular Medicine Engineering Research Center

提出更正下载数据